For the first time ever, Mount Sinai researchers have identified a protein as a marker that can indicate whether a cancer patient will develop a reoccurrence of lethal, metastatic cancer, according to a clinical study published in Breast Cancer Research in October.
The researchers found that when cells from a breast cancer patient’s original tumor metastasized into the patient’s bone marrow with none, or only a small amount, of the protein NR2F1, the patients all soon died. However, patients who had a high concentration of NR2F1 in the cancer cells in their bone marrow did not frequently develop this type of metastatic cancer, and lived longer. The presence of a high concentration of NR2F1 induced dormancy in the cancer cells, essentially deactivating them, so this research shows that survival in these patients is due to the dormancy of the disseminated cancer.
These findings suggest that the absence of this protein in cancer cells that have spread to a patient’s bone marrow can reliably signal that the patient will relapse soon and that additional treatment is needed, while if the protein is present, the cancer cells are dormant and the patient can be monitored rather than undergo unnecessary treatment. This research is particularly important because the most common breast type of breast cancer, when it metastasizes, almost always goes to the bone.
The research is especially important in the United States because bone marrow tests, called aspirates, are not used to monitor patients there. The study was a collaboration with physicians and scientists in Oslo, Norway, where bone marrow aspirates are used to monitor patients. The laboratory of Bjorn Naume from University Hospital of Oslo collaborated with the Aguirre-Ghiso and Sosa labs at the Icahn School of Medicine at Mount Sinai and conducted the analysis of the patients’ samples from their clinical trials, thus contributing significantly to this research.
Using this research, physicians could monitor their patients with bone marrow aspirates. Tests for the protein could also help clinicians identify patients who may benefit from recently identified drugs that were shown to target cancer cells and render or keep them dormant. Studies have already shown that androgen deprivation treatment, an anti-hormone therapy used in prostate cancer, has been linked to increasing levels of the NR2F1 protein. Mount Sinai, through a trial funded by the V Foundation for Cancer Research and The Tisch Cancer Institute at the Icahn School of Medicine, has already begun recruiting prostate cancer patients for a test of the ability of two drugs to induce dormancy through NR2F1 upregulation. “This research shows that the survival advantage in these patients is due to high levels of this protein. Tests using this protein marker could further improve curative treatment of breast cancer, sparing patients from unnecessary treatments. Identifying patients with disseminated disease that is not yet symptomatic and characterizing it for potential dormancy or metastatic recurrence is a game changer,” said lead researcher Julio Aguirre-Ghiso, PhD, Director of Solid Tumor and Metastasis Research, Director of Head and Neck Cancer Basic Research, and Professor of Oncological Sciences, Otolaryngology, and Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute at the Icahn School of Medicine. “Improved techniques to assess the population of patients with residual disease and their dormant or reactivating state will be key to identifying the risk of future metastasis despite undergoing standard treatment. This opens the way for testing new treatments that prevent metastasis by inducing dormancy or eradicating the dormant disseminated cancer cells that have not yet initiated metastatic growth.”
The Latest on: Breast cancer
via Google News
The Latest on: Breast cancer
- Breast cancer survivor credits journey to mammograms, advances in breast cancer researchon February 27, 2020 at 7:26 pm
BATON ROUGE, La. (WAFB) - Less than one year ago, Louann Bombet went in for her annual mammogram. That’s when her doctor noticed something suspicious and asked her to come back for a follow up ...
- Breast Cancer Conference Brings Young Survivors Togetheron February 27, 2020 at 7:03 pm
brings its fifth annual conference to Los Angeles, California, March 6-8, 2020, where it will host more than 600 young adults affected by breast cancer and their co-survivor support networks. Online ...
- Dairy milk could increase the risk of breast canceron February 27, 2020 at 1:38 pm
A new study suggests women who drink dairy milk may be at greater risk of breast cancer than those who drink little or no milk.
- Capicua restricts cancer stem cell-like properties in breast cancer cellson February 27, 2020 at 9:17 am
All prices are NET prices. VAT will be added later in the checkout. Fig. 2: CIC regulates BCSC-like features. Fig. 3: Deficiency of CIC relieves repression of ETV4 and ETV5 expression in breast cancer ...
- Augusta woman creates crowns made of bedazzled bras for "Boobie Queens" going through breast cancer treatmenton February 27, 2020 at 7:37 am
Nearly 12% of women in the US will be diagnosed with breast cancer in their life, but one Augusta woman is trying to turn each case into something a little more lighthearted.
- Keytruda shows promise against aggressive breast canceron February 27, 2020 at 6:17 am
The immunotherapy drug Keytruda might offer a new treatment option to women with an aggressive form of breast cancer, a clinical trial suggests. The study found that for women with "triple-negative" ...
- Global Advances in Breast Cancer Detection Creating $5.13 Billion Opportunityon February 27, 2020 at 5:50 am
PALM BEACH, Florida, Feb. 27, 2020 /PRNewswire/ -- Globally, breast cancer effects 2.1 million women every year. In 2018 alone, it was the cause of nearly 627,000 deaths, according to the World Health ...
- Milk and breast cancer: Is there a link?on February 27, 2020 at 3:14 am
A recent study concludes that women who drink greater amounts of milk might have an increased risk of developing breast cancer than those who drink little or no milk. Share on Pinterest Could drinking ...
- VEGF-A165b levels are reduced in breast cancer patients at primary diagnosis but increase after completion of cancer treatmenton February 27, 2020 at 2:26 am
The antiangiogenic splice variant VEGF-A165b is downregulated in a variety of cancer entities, but little is known so far about circulating plasma levels. The present analysis addresses this question ...
via Bing News